- Home
- STX vs INSM Comparison
STX vs INSM Comparison
Compare STX & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STX
- INSM
- Stock Information
- Founded
- STX 1978
- INSM 1988
- Country
- STX Singapore
- INSM United States
- Employees
- STX N/A
- INSM N/A
- Industry
- STX Electronic Components
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- STX Technology
- INSM Health Care
- Exchange
- STX Nasdaq
- INSM Nasdaq
- Market Cap
- STX 15.5B
- INSM 14.3B
- IPO Year
- STX 2002
- INSM 2000
- Fundamental
- Price
- STX $75.78
- INSM $72.65
- Analyst Decision
- STX Buy
- INSM Strong Buy
- Analyst Count
- STX 20
- INSM 16
- Target Price
- STX $122.63
- INSM $95.36
- AVG Volume (30 Days)
- STX 4.8M
- INSM 2.2M
- Earning Date
- STX 04-29-2025
- INSM 05-08-2025
- Dividend Yield
- STX 3.80%
- INSM N/A
- EPS Growth
- STX N/A
- INSM N/A
- EPS
- STX 5.45
- INSM N/A
- Revenue
- STX $8,035,000,000.00
- INSM $363,707,000.00
- Revenue This Year
- STX $37.69
- INSM $30.16
- Revenue Next Year
- STX $12.79
- INSM $115.67
- P/E Ratio
- STX $13.90
- INSM N/A
- Revenue Growth
- STX 24.17
- INSM 19.17
- 52 Week Low
- STX $63.19
- INSM $21.92
- 52 Week High
- STX $115.32
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- STX 43.99
- INSM 49.90
- Support Level
- STX $71.30
- INSM $60.40
- Resistance Level
- STX $75.23
- INSM $71.98
- Average True Range (ATR)
- STX 4.87
- INSM 4.21
- MACD
- STX 0.39
- INSM 0.21
- Stochastic Oscillator
- STX 54.38
- INSM 75.15
About STX Seagate Technology Holdings PLC (Ireland)
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.